US Patent 9493565 Targeted binding agents against B7-H1
Patent 9493565 was granted and assigned to Medimmune Limited on November, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Dec, 2023
Golden AI
Edits made to:
Article (+301 characters)
Article
Patent abstract
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Infobox
Patent Inventor Names
Christophe Queva0
Ian Nevin Foltz0
Jaspal Singh Kang0
John Babcock0
Kathleen Ann Mulgrew0
Laura Sekirov0
Marat Alimzhanov0
Matthieu Chodorge0
Melanie Boyle0
Michelle Morrow0
Ross A. Steward0
Scott Hammond0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09493565 Targeted binding agents against B7-H1 US Patent 9493565 Targeted binding agents against B7-H1
Infobox
Patent Number
09493565
Patent Number
9493565
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09493565 Targeted binding agents against B7-H1
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09493565
Date of patent
November 15, 2016
Patent application number
14271108
Date Filed
May 6, 2014
Patent primary examiner
Find more entities like US Patent 9493565 Targeted binding agents against B7-H1
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.